Acute kidney injury (AKI) refers to an abrupt loss of kidney function, resulting in the build-up of waste products in the blood that would normally be removed by the kidneys. It is a serious condition that requires prompt medical care to prevent further kidney damage and failure. Global acute kidney injury treatment market growth is driven by rising prevalence of comorbid conditions such as diabetes and hypertension that increases the risk of AKI. Furthermore, development of novel drugs and treatment approaches has expanded therapeutic options for patients. However, lack of awareness among people and healthcare providers about AKI can hamper the market growth.

Market Dynamics:

Global acute kidney injury treatment market growth is driven by rising geriatric population who are more susceptible to AKI due to age-related decline in kidney function. According to the United Nations, the number of people aged 65 years and above is projected to reach over 1.5 billion by 2050. Growing prevalence of chronic kidney diseases due to lifestyle changes can also drive the market growth. However, high costs associated with renal replacement therapies can limit widespread adoption. Lack of awareness about early diagnosis of AKI can hamper the market growth. Development of biomarkers for early detection of AKI presents lucrative opportunities for market players to expand their offerings in this area. Real-time monitoring of fluid status offers real-time customized care. Digital health solutions can also aid remote patient management.

Key features of the study:

- This report provides in-depth analysis of the global acute kidney injury treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global acute kidney injury treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Fresenius Medical Care AG & Co. KGaA, Baxter, Angion Biomedica Corp, AM-Pharma, and Quark Pharmaceuticals, Inc.

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global acute kidney injury treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute kidney injury treatment market

 Detailed Segmentation-

• Type Insights (Revenue, USD Bn, 2019 - 2031)
• • Prerenal Acute Kidney Injury
  • Intrinsic Renal Acute Kidney Injury
  • Postrenal Acute Kidney Injury
•  Treatment Insights (Revenue, USD Bn, 2019 - 2031)
• • Therapy
  • Drugs
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Angion Biomedica Corp.
  • AM-Pharma
  • Quark Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Braun Melsungen AG
  • Asahi Kasei Medical Co., Ltd.
  • LG Chem
  • Kringle Pharma, Inc.
  • AstraZeneca
  • Amgen Inc.
  • Gilead Sciences
  • Roche
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Novartis AG
  • AbbVie Inc.